News

January 19, 2018

SMA Industry Collaboration Releases Spinal Muscular Atrophy Voice of the Patient (VoP) Report

SMA Industry Collaboration Releases Spinal Muscular Atrophy Voice of the Patient (VoP) Report

Cure SMA and our partners in the SMA Industry Collaboration are pleased to announce the release of the Spinal Muscular Atrophy Voice of the Patient (VoP) Report. This report is a thorough written account...

READ MORE   |  

Topics: Our Impact, Advocacy, Front Page News

January 17, 2018

2018 Updated SMA Drug Pipeline Released

2018 Updated SMA Drug Pipeline Released

We’ve recently released an update to the SMA drug pipeline. This latest version includes:

  • 16 active programs, including one approved therapy. 
  • 14 pharmaceutical partners.
  • 6 programs in clinical trials.
  • An ever-increasing breadth of...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

January 16, 2018

AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

AveXis, a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today provided an overview of the expanded clinical development program for the company’s initial gene therapy candidate, AVXS-101, for...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

Items 1 - 3 of 422  12345678910Next

© 2018 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software